Cosopt PF

Quick links to important sections

Cosopt PF

Treatment option: Glaucoma

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cosopt PF

What is Cosopt PF?

Cosopt PF is an ophthalmic solution used to manage increased pressure within the eye. It is a combination medication containing two active ingredients: dorzolamide hydrochloride and timolol maleate.

Mechanism of Action

The two components of Cosopt PF work through different mechanisms to achieve a common goal of reducing intraocular pressure:

  • Dorzolamide hydrochloride: This is a carbonic anhydrase inhibitor. It works by decreasing the production of aqueous humor, the fluid found inside the front part of the eye.
  • Timolol maleate: This is a beta-adrenergic receptor blocking agent. It also contributes to lowering eye pressure by reducing the rate at which fluid is secreted into the eye.

By combining these two agents, the medication provides a dual approach to controlling eye pressure that is often more effective than using either component alone.

The "PF" Designation

The "PF" in the name stands for preservative-free. Traditional eye drops often contain preservatives, such as benzalkonium chloride, to maintain sterility in multi-dose bottles. However, some individuals are sensitive to these preservatives, which can cause ocular irritation or damage to the surface of the eye. Cosopt PF is supplied in single-use containers to ensure sterility without the need for added preservative chemicals.

Clinical Applications

This medication is primarily used for individuals with conditions characterized by high internal eye pressure, such as:

  • Open-angle glaucoma: A chronic condition where fluid does not drain properly, leading to progressive pressure increase.
  • Ocular hypertension: A state where the pressure inside the eye is higher than the normal range, increasing the risk of developing glaucoma.

Regulatory References

  1. MedlinePlus Drug Information
  2. NIH DailyMed Entry

What side effects are possible with Cosopt PF?

Possible Side Effects and Safety Information

The safety profile for this fixed-combination ophthalmic solution is defined by the systemic absorption of its two active components, Dorzolamide (a sulfonamide) and Timolol (a non-selective beta-blocker), even with topical administration.


Documented Adverse Reactions

The most frequently reported local adverse reaction, classified as Very Common in official labeling, is ocular burning and stinging. Other effects classified as Common include conjunctival hyperemia (eye redness), blurred vision, superficial punctate keratitis, eye itching, and the systemic effect of taste perversion [MedlinePlus Drug Information].

Side effects are grouped by system-organ class as documented in regulatory sources:

System/Organ Class Examples of Documented Effects
Eye Disorders Blurred vision, dry eyes, eyelid inflammation
Gastrointestinal Disorders Taste perversion, dry mouth
Nervous System Disorders Headache, dizziness, depression
Cardiac Disorders Changes in heart rate and rhythm, sinus bradycardia
Respiratory Disorders Dyspnea (shortness of breath), nasal congestion

Serious Safety Considerations

The systemic absorption of the beta-blocker component means the medicine carries the potential for rare, severe adverse events, including cardiac failure and bronchospasm (severe airway narrowing) in patients with pre-existing respiratory disease. The sulfonamide component is associated with rare, severe systemic reactions, such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis [COSOPT - accessdata.fda.gov].

Official labeling notes caution for specific populations: the medicine is not recommended in individuals with severe renal impairment and may mask signs of acute hypoglycemia in diabetic patients [Reference ID: 3080555].

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Cosopt PF (dorzolamide hydrochloride and timolol maleate ophthalmic solution) may result from excessive topical use or accidental oral ingestion, potentially leading to systemic effects from both active components. Seek immediate medical attention if overdose is suspected or if systemic symptoms occur, as required by regulatory authorities.

Documented Manifestations and Emergency Actions

The most serious outcomes are associated with the timolol component, a beta-blocker, due to the potential for severe systemic effects. Officially documented manifestations include bradycardia (abnormally slow heart rate), hypotension (low blood pressure), cardiac failure, and bronchospasm. Life-threatening outcomes such as cardiac arrest are documented in regulatory labeling.

Overdose from the dorzolamide component may lead to drowsiness and metabolic acidosis, which can be exacerbated in patients with renal impairment. Other documented signs include confusion and electrolyte imbalance.

In case of accidental oral ingestion, contact emergency services immediately, particularly if signs of serious effects—such as a seizure or trouble breathing—are present. No specific antidote is known for this fixed-combination product. Treatment must be symptomatic and supportive, including monitoring of serum electrolytes and continuous observation of cardiac and respiratory status, as outlined in official prescribing information.

Therapeutic Uses of Cosopt PF

What Cosopt PF Treats: Main Uses and Benefits

Cosopt PF (dorzolamide hydrochloride and timolol maleate ophthalmic solution) is a combined therapy used primarily to reduce elevated intraocular pressure (IOP), which is a primary symptomatic domain it addresses. The medication is indicated for patients with open-angle glaucoma or ocular hypertension.


Key Areas of Symptom Management

Cosopt PF is applied across domains where additional symptomatic support is needed, specifically for managing the elevated pressure associated with chronic open-angle glaucoma and episodic ocular hypertension. This medication helps address symptoms related to heightened physiological activity and is commonly used when symptoms intensify and supportive relief is needed.

It contributes to improved comfort during periods of intraocular tension and offers supportive relief that helps patients cope more steadily with their condition. It is relevant in clinical contexts marked by increased discomfort or tension, assisting with maintaining functional stability.


Quick Fact: Relief for Elevated Intraocular Pressure (IOP)

This supportive management provides a therapeutic benefit by helping to ease the overall symptom load of high eye pressure and may assist with maintaining functional stability.

Regulatory References

  1. DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE solution/drops

Eligibility and Restrictions for Use

The eligibility to use Cosopt PF is strictly governed by the potential systemic effects of its active ingredients, Timolol (a beta-blocker) and Dorzolamide (a sulfonamide). The medicine is approved for use in adults with open-angle glaucoma or ocular hypertension.

Populations for Whom Use is Contraindicated

The following groups must not use Cosopt PF, based on absolute contraindications in regulatory labeling:

  • Patients with bronchial asthma or a history of asthma, or severe chronic obstructive pulmonary disease (COPD).
  • Patients with specific severe cardiac conditions, including sinus bradycardia, second or third-degree atrioventricular (AV) block, overt cardiac failure, or cardiogenic shock.
  • Individuals with hypersensitivity to any component of the product.

Condition-Specific and Age Restrictions

Use is not recommended for patients with severe renal impairment (CrCl < 30 mL/min) and should be used with caution in those with hepatic impairment, as the medicine has not been studied in these populations. Safety and efficacy have not been established in children under 2 years of age. For pregnancy, use is limited to situations where the potential benefit justifies the risk, and a decision to discontinue nursing or the drug must be made when breastfeeding, as Timolol is detected in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Cosopt PF based on the systemic effects of its active components, dorzolamide (a carbonic anhydrase inhibitor) and timolol (a non-selective beta-blocker).

Pharmacodynamic Interactions (Additive Effects)

Co-administration with agents having similar systemic effects is documented to increase the risk of additive pharmacodynamic outcomes. This includes using Cosopt PF with oral carbonic anhydrase inhibitors, which may increase the risk of acid-base and electrolyte disturbances. The combination with systemic beta-blockers (oral or ophthalmic) increases the risk of enhanced systemic beta-blockade effects. Furthermore, concomitant use with calcium antagonists, digitalis, or catecholamine-depleting drugs (such as reserpine) may lead to additive effects on atrioventricular conduction or blood pressure.

Pharmacokinetic Interactions and Restrictions

Co-administration with potent CYP2D6 inhibitors (including quinidine, fluoxetine, and paroxetine) is documented to increase the systemic exposure and plasma concentration of the timolol component. This is a pharmacokinetic interaction pattern. When used alongside other topical ophthalmic drugs, a separation of at least five minutes between administrations is required. Cosopt PF is not recommended for patients with severe renal impairment (CrCl < 30 mL/min) due to the potential for the accumulation of the dorzolamide metabolite.

Mechanism of Action

Dual Mechanism to Suppress Aqueous Humor Production

Cosopt PF operates via two distinct mechanisms within the ciliary body, the tissue responsible for creating aqueous humor. The formulation contains Dorzolamide, an inhibitor, and Timolol, an antagonist, providing a dual approach to reducing fluid secretion.

Modulating Fluid Homeostasis via Carbonic Anhydrase Inhibition

Dorzolamide targets and inhibits the Carbonic Anhydrase II ( CA-II) enzyme. This enzyme inhibition disrupts the bicarbonate ion transport pathway ( HCO3^-) that is essential for active fluid secretion. The resulting decrease in HCO3^- availability leads to a downregulation of aqueous humor formation.

Antagonism of Sympathetic Signaling in Ocular Dynamics

Timolol is a non-selective beta-adrenergic receptor antagonist (beta1 and beta2). By blocking these receptors, it interrupts the sympathetic signaling cascade that utilizes cyclic AMP ( cAMP) to stimulate fluid production. This beta-receptor blockade causes a reduction in the secretory drive, complementing the enzyme inhibition for a dual-action mechanism influencing ocular fluid balance and resulting in a decrease in hydrostatic pressure within the eye.

Dosage and Administration Information

Administration and Dosage Instructions for Cosopt PF

Cosopt PF (dorzolamide/timolol ophthalmic solution) is for topical ophthalmic use only. It must be administered as one drop in the affected eye(s) two times daily (morning and evening), or exactly as prescribed by a healthcare provider.


Procedural Requirements

Cosopt PF is supplied in single-use containers that are preservative-free. The solution from one individual unit must be used immediately after opening for administration to one or both eyes. Since sterility cannot be maintained after the individual unit is opened, the remaining contents must be discarded immediately after administration.

When administering, patients must take care not to allow the tip of the container to touch the eye or any surrounding surfaces to prevent contamination. If other topical ophthalmic drugs are being used, they should be administered at least five minutes apart from Cosopt PF to prevent the washing out of medication.


Missed Dose and Age-Specific Use

If a dose is missed, the patient should instill the missed dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule should be resumed. A double dose should not be instilled to make up for a missed one.

For adults, the dosing schedule is one drop in the affected eye two times a day. Use and dose for children younger than 2 years of age must be determined by a doctor.

Recent Clinical Evidence

Cosopt PF: Recent Clinical Evidence

Recent clinical research has focused on the efficacy and tolerability of the fixed-combination of dorzolamide 2% and timolol 0.5% without preservatives (PF formulation) in patients with elevated intraocular pressure (IOP), specifically those with ocular hypertension or open-angle glaucoma.


IOP Reduction and Efficacy

Clinical trials have demonstrated that the preservative-free formulation provides IOP-lowering effects comparable to those of the preserved dorzolamide/timolol combination. In a 3-month randomized controlled trial involving patients with glaucoma, the PF formulation was shown to achieve a reduction in IOP that was not statistically different from the preserved counterpart.

Studies also evaluated patients who were switched from preserved anti-glaucoma medications to the PF formulation. Following the switch, sustained IOP control was reported in conjunction with improvements in ocular comfort metrics.


Ocular Tolerability and Safety

The primary focus of recent research is the tolerability benefit of the PF formulation. Chronic use of preserved eye drops, particularly those containing benzalkonium chloride (BAK), is associated with ocular surface disease (OSD) symptoms, such as burning, stinging, and itching.

Comparative studies and observational data indicate that the PF formulation is associated with fewer reported drug-related adverse events and an improvement in ocular surface health compared to preserved equivalents. This improved tolerability may be relevant for patients who have sensitivity to preservatives or pre-existing ocular surface conditions.

Frequently Asked Questions (FAQ)

Common questions about Cosopt PF (FAQ)

Q: How is Cosopt PF different from regular Cosopt?

A: Cosopt PF is a preservative-free (PF) formulation, meaning it does not contain the preservative benzalkonium chloride (BAK). This preservative is found in the non-PF version of the medicine. The preservative-free product is supplied in individual single-use containers to ensure sterility.

Q: Why is Cosopt PF prescribed over a single-ingredient eye drop?

A: Official product information indicates that this fixed-combination medicine is used in certain patients when a single-ingredient beta-blocker eye drop is not sufficient to control elevated eye pressure (IOP). The combination of two different active ingredients provides an additive pressure-lowering effect. This dual action can help achieve target pressure levels when a single drug is inadequate.

Q: Is there evidence about Cosopt PF helping to preserve vision?

A: Official documentation states that the medicine is indicated for the reduction of elevated intraocular pressure (IOP). The main goal of treating elevated IOP is to help manage conditions like glaucoma and reduce the risk of further damage. By lowering pressure, the medicine addresses the primary risk factor for vision deterioration in these conditions.

Q: What is the significance of Cosopt PF being typically used twice a day?

A: The twice-daily frequency is the specific regimen used in clinical trials to help maintain the pressure-lowering effect throughout the entire 24-hour period. This administration pattern is the established regimen for the medicine.

Q: Can Cosopt PF be used by older adults?

A: According to official regulatory information, studies performed to date have not demonstrated geriatric-specific problems that would limit its use in older adults. The regulatory documents state that the dosing for older adults is typically the same as the standard adult regimen.

Q: Can people who wear contact lenses use Cosopt PF?

A: The product is a preservative-free (PF) formulation. Because of this formulation, it is often not necessary to remove soft contact lenses before administering the eye drops. This is a key difference from preserved eye drops, which usually require the removal of contacts before use.

Q: Is there a generic version of Cosopt PF available?

A: Official sources confirm that the fixed-combination of dorzolamide and timolol is available as a generic medication. This includes generic equivalents of the preservative-free (PF) formulation, offering an alternative to the brand name product.

Q: Is Cosopt PF the same type of medication as Latanoprost?

A: Cosopt PF is a fixed combination of two different drug classes: a carbonic anhydrase inhibitor (dorzolamide) and a beta-blocker (timolol). This makes it a different pharmacological type than medicines such as Latanoprost, which belongs to the prostaglandin analog class.

Q: Are there any restrictions on driving or operating machinery while using Cosopt PF?

A: Official labeling notes that the medicine can cause side effects such as blurred vision and dizziness. Because of these potential effects, the regulatory information indicates that caution is appropriate regarding driving or operating machinery until the user knows how the medicine affects their vision and alertness.

Q: What research has been done on the long-term safety of Cosopt PF?

A: Clinical evidence has primarily focused on comparing the preservative-free (PF) product to the preserved version. Studies have examined the sustained pressure control and the ocular tolerability benefits of the PF formulation over multi-month treatment periods.

Q: What is the difference between Cosopt PF and its generic equivalent, Dorzolamide/Timolol PF?

A: Regulatory sources define a generic equivalent as having the same active ingredients (dorzolamide 2% and timolol 0.5%), strength, dosage form, and route of administration as the brand-name product. The active medication within the drops is chemically the same.

Q: Can I travel with Cosopt PF?

A: Regulatory storage requirements state that the medicine should be protected from freezing and kept at controlled room temperature (20 C to 25 C). The single-use containers within an opened foil pouch must be used within 15 days of opening that pouch, which is an important consideration for travel.

Q: Is it safe to drink alcohol while using Cosopt PF?

A: The medicine is known to cause central nervous system side effects such as dizziness and headache. Official regulatory information for similar medicines indicates that combining drugs with known CNS effects with alcohol may increase these known risks.

Q: What official medical bodies have approved Cosopt PF?

A: The core regulatory documentation is provided by the U.S. Food and Drug Administration (FDA). The medicine is also reviewed and regulated by corresponding government bodies in other regions where it is sold.

Q: Do patients typically experience an adjustment period when they start Cosopt PF?

A: The most frequently reported local side effect is ocular burning and stinging, which patients may experience when they first start using the medicine. These are documented as Very Common adverse reactions in the official safety profile.

Q: How does Cosopt PF compare to drops that work by increasing fluid outflow?

A: The mechanism of Cosopt PF is a dual action that works to decrease the rate of fluid (aqueous humor) secretion inside the eye. This approach to pressure reduction is different from other glaucoma medicines that work primarily by increasing the outflow of fluid.

Q: What happens if the eye drop solution looks cloudy or changes color?

A: Official product safety notes that the solution should be clear, colorless, or nearly colorless. Regulatory information notes that if the medicine appears cloudy or changes color, the single-use container is to be discarded and not administered.

How should Cosopt PF be stored and disposed of?

Storage and Disposal Requirements

Cosopt PF, a preservative-free ophthalmic solution, requires strict adherence to official storage and disposal rules to maintain sterility and potency.

Classification Official Regulatory Wording / Requirement
Storage Temperature Store at controlled room temperature (20 C to 25 C). Do not freeze or store above 30 C.
Protection Keep single-use containers in the original foil pouch to protect from light.
In-Use Stability The remaining containers in the opened foil pouch must be used within 15 days.
Child Safety Keep out of the reach and sight of children.
Disposal Discard the individual opened container immediately after administration. Do not dispose of unused or expired medicine in wastewater or household waste; consult a pharmacist for proper pharmaceutical waste handling.

The regulatory profile mandates storing the unopened product within the specific room temperature range and protecting it from light and freezing. Due to the preservative-free nature, the contents of the individual unit must be discarded immediately after use, and the remaining units in the opened pouch must be used within a 15-day limit. Official disposal procedures strictly prohibit discarding the medicine into household waste streams.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cosopt PF found in:

A-Z Index: